Rezurock (belumosudil) / Meiji Seika, Nano Terra, Romeck Pharma, BioNova Pharma, Sanofi - LARVOL DELTA

Belumosudil in pediatric patients with steroid-refractory chronic graft-versus-host disease (ASH 2025) - "Belumosudil was well tolerated and the AE rates were comparable between the belumosudil and the control groups. Belumosudil was effective and well tolerated in pediatric patients with SR-cGVHD, and similar efficacy and safety was also confirmed in the patients aged<12 years old."

Clinical • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Pediatrics

Real-world effectiveness of belumosudil for chronic GVHD by line of treatment: Analysis of academic and community practice patterns (ASH 2025) - "The most common treatment prior to BEL was ruxolitinib (RUX) alone or in combination with calcineurin inhibitors (CNIs) or glucocorticoids (GCs), which was consistent across all LOTs. These real-world data demonstrate consistent use of BEL across practice settings, including frequent use of BEL subsequent to treatment with RUX and GCs. The extent of concurrent use of BEL and RUX remains to be further elucidated before the frequency of this approach in real-world management of advanced cGVHD can be fully characterized. In spite of common use of RUX in pre-BEL LOT, ROCKreal data confirm clinically significant 6 month response rates in patients receiving BEL in LOT 3 and LOTs 4-6."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

Early detection of emerging safety signals in GVHD prophylaxis agents using a 12-year faers "slope-watch" approach (ASH 2025) - "In addition to tacrolimus and cyclosporine, contemporary prophylaxis regimens employ sirolimus and everolimus, mycophenolate mofetil, methotrexate, post-transplant cyclophosphamide (PTCy), JAK inhibitors (ruxolitinib, baricitinib, tofacitinib), co-stimulation blockade with abatacept, gut-homing integrin antagonism via vedolizumab, and the ROCK2 inhibitor belumosudil. Sequential IC-Δ offers a robust, forward-looking pharmacovigilance framework that identifies adverse event acceleration 12–24 months before regulatory action. By emphasizing directional change and incorporating a simple confidence approximation, this approach enhances early signal detection in large safety datasets. Integration with electronic health records, regulatory pipelines, and interactive dashboards could further streamline horizon scanning and improve patient safety in GVHD prophylaxis."

Clinical • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Dyslipidemia • Graft versus Host Disease • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Pneumonia • Rare Diseases • Respiratory Diseases • Septic Shock

Real-world effectiveness and corticosteroid-sparing effects of belumosudil in chronic gvhd: A multi-database analysis (ASH 2025) - "We found BEL to be most often used concurrently with GC among cGVHD patients receiving therapy in LOT 3-6. ROCKreal data points at GC reduction or discontinuation potential with the use of BEL in the majority of treated patients in concordance with previously published studies. By reducing long-term GC exposure, the use of BEL holds promise to lessen the burden of GC-related adverse events, thereby potentially mitigating morbidity and improving the quality of life for patients with cGVHD."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Chronic Graft versus Host Disease • Diabetes • Graft versus Host Disease • Immunology • Metabolic Disorders

Large language models extract diverse manifestations of chronic GVHD from unstructured clinical documentation (ASH 2025) - "Of these patients, 58 were steroid refractory/dependent and received a second line immunosuppressant such as ruxolitinib (76% of patients), belumosudil (14%), or ibrutinib (16%). Presence of any non-scorable symptom (i.e. muscle symptom, nasal/sinus symptoms, serositis, or capillary leak syndrome) in the two weeks leading up to the start of corticosteroid therapy occurred more frequently in patients who required additional immunosuppression (11/58, 19.0%) compared those who received prednisone alone (6/85, 7.1%) with an odds ratio of 0.32 (pvalue 0.04)...This approach enabled the construction of a comprehensive database of events post-transplant. We anticipate that this database will facilitate future investigation into distinct patterns of cGVHD activity, creating well-calibrated metrics of disease severity, and predicting response to immunosuppressive therapy."

Clinical • Cardiovascular • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Otorhinolaryngology

The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory chronic graft-versus-host disease (ASH 2025) - "High response rates (ORR 54.8%, best ORR 76.2%), durable disease control (12-month FFS 92.5%), and significant CS reduction (median 70.8% dose decrease) were achieved without severe toxicity (grade ≥3 infections: 4.8%; no treatment discontinuations). These findings support the mechanistic rationale for concurrent JAK/ROCK inhibition and warrant prospective validation."

Clinical • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Fibrosis • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Leukopenia • Pneumonia • Respiratory Diseases

Investigating belumosudil in children with refractory moderate-to-severe chronic graft-versus-host disease: Design of a phase 1/2 study (ASH 2025) - "RPED determination in Phase 1 will provide dosing details for Phase 2. Enrollment and follow-ups are also in progress."

Clinical • P1/2 data • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hepatitis B • Hepatology • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • CYP3A4

Belumosudil is effective in patients with chronic graft-versus-host disease lasting more than two years: A retrospective single-center real-world study (ASH 2025) - "Resistance to the most recent prior therapy (including glucocorticoid, calcineurin inhibitors, mycophenolate mofetil, ruxolitinib, mesenchymal stem cells, etc.) was observed in 82.4% (n = 14). This real-world study demonstrates that belumosudil is efficacious, well-tolerable, and safe for recipients with cGVHD persisting for at least 2 years after diagnosis and following multiple lines of anti-cGVHD therapy. Most patients exhibit meaningful clinical improvement with belumosudil. No significant increase in the risk of disease recurrence or infection was observed."

Real-world • Real-world evidence • Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia

Line-of-therapy stratified efficacy of belumosudil in cgvhd : Real-world evidence (ASH 2025) - "For concomitant treatments, cyclosporine was more frequent in patients with 1 prior LOT (73.3% vs. 22.2%, P=0.033), whereas tacrolimus was more common in patients with ≥2 prior LOTs (13.3% vs. 66.7%, P=0.021). No statistically significant differences were observed for other concomitant treatments, including corticosteroid (73.3% vs. 33.3%, P=0.092), mycophenolate mofetil (80.0% vs. 66.7%, P=0.635) and JAK inhibitor (33.3% vs. 44.4%, P=0.678)... In this real-world analysis dedicated to pretreated cGVHD, belumosudil achieved 95.8% (23/24) ORR in overall cohort, with 100% ORR specifically in second-line therapy (15/15). The 88.9% ORR in patients with ≥2 prior LOTs (8/9), 41.7% steroid reduction, and no grade≥3 AEs support its prioritization for early second-line use."

Clinical • HEOR • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

Effectiveness of belumosudil in acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT): A real-world observational study (ASH 2025) - "All patients received myeloablative conditioning, with 75% of patients administered the fludarabine plus modified TBI regimen incorporating craniospinal, marrow, and nodal targets. Standard GVHD prophylaxis was cyclosporine/MMF/methotrexate + anti-CD25/ATG/ALG...Conclusion : This study provides the first disclosed real-world evidence of belumosudil in acute GVHD, demonstrating unprecedented 100% ORR (75% cases with a complete response) with rapid median time to response of 13.5 days and well tolerated. Despite the inherent limitations of this pilot investigation, these findings warrant validation in pivotal multicenter trials."

Clinical • Observational data • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dermatology • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Respiratory Diseases • Transplantation • CD80 • CD86 • IL17A • IL21 • STAT5

The effect of belumosudil on the therapeutic monitoring of tacrolimus and sirolimus in allogeneic hematopoietic transplantation (ASH 2025) - "Azoles were used concomitantly in 51.5% of patients (35/68), with 65.7% (23/35) on posaconazole, 31.4% (11/35) on isavuconazole, and 2.9% (1/35) on voriconazole. Four patients started an azole after starting belumosudil (2 on posaconazole, 1 on fluconazole, and 1 on isavuconazole)... Our study confirms the drug interaction between TAC/SIRO, with the increase in TAC/SIRO levels more pronounced with the second level after starting belumosudil. However, severe toxicities were rarely seen. Based on our data, we recommend close TDM of TAC and SIRO, but no dose adjustment is warranted when belumosudil is added."

Acute Kidney Injury • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Movement Disorders • Nephrology • Transplantation • CYP3A4

Plasmacytoid dendritic cell in a setting of acute myeloid leukaemia: A single-center case series from tertiary cancer hospital (ASH 2025) - "All patients received intensive induction therapy, including 3+7, FLAG-IDA, or venetoclax-based regimens , and three underwent haploidentical allogeneic stem cell transplantation in first complete remission...One of these patients developed chronic lung graft-versus-host disease and remains on therapy with ruxolitinib and belumosudil... AML with plasmacytoid or plasmacytic differentiation is a rare but clinically relevant subset that spans diverse genetic and molecular backgrounds and may behave more aggressively than suggested by standard ELN risk classifications. Some patients with favorable-risk cytogenetics experienced poor outcomes, highlighting the limitations of current risk models in this group. Accurate recognition requires the use of extended immunophenotyping panels including markers such as CD123, CD303, CD43, and CD68 to distinguish this phenotype from entities like BPDCN."

Clinical • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Septic Shock • ANPEP • CD123 • CD14 • CD33 • CD34 • CD68 • CD7 • CLEC4C • FLT3 • IL3RA • ITGAM • KIT • KRAS • NCAM1 • NPM1 • NRAS • SPN

Propensity score matching analysis comparing the efficacy and treatment outcomes of belumosudil treatment with ruxolitinib therapy as second-line or beyond in chronic GVHD patients after steroid failure (ASH 2025) - "Introduction Belumosudil (BEL), a selective Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, has been approvedas 3rd line or beyond treatment option for steroid-refractory (SR) chronic graft-versus-host disease(cGvHD), while ruxolitinib (RUX), JAK1/2 inhibitor, has been an established treatment of choice as 2nd linefor SR-cGvHD. Similarly, an HCT-CI ≥ 3 (HR 4.584[1.926–10.91] p<0.001) and severe grade cGvHD (HR 8.082 [1.723–37.92], p=0.008) were identified asadverse prognostic factors for OS.In PSM subgroup, 19.6% (33.9% vs. 14.3%, p=0.007) and 18.1% (41.2% vs. 23.1%, p=0.044) more patientsin BEL group could discontinue prednisone at months 3 and 6, compared to RUX group, respectively.ConclusionThe current study showed no difference for FFS or OS between BEL and RUX as second-line therapy orbeyond in cGvHD patients after therapy failure. However, it is noteworthy that steroid tapering could befaster in BEL compared to RUX."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

Real-world effectiveness and safety of belumosudil in pediatric chronic graft-versus-host disease: A retrospective cohort study (ASH 2025) - "Most patients hadconcurrent medications, including corticosteroids (80%), tacrolimus (43.3%), and ruxolitinib (40%).Responses were reported in 22 patients (73.3%, 95% CI: 54.1%-87.7%), including 1 complete responseand 21 partial responses. Belumosudil showed favorable response and safety in pediatric cGVHD patients in the real-world practice, with clinically meaningful symptom improvement and corticosteroid-sparing effects. Thetreatment was also effective in children under 12 years of age. These real-world findings support the useof belumosudil as a valuable therapeutic option for pediatric cGVHD patients."

Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Anorexia • Bone Marrow Transplantation • Cardiovascular • Chronic Graft versus Host Disease • Fibrosis • Gastrointestinal Disorder • Graft versus Host Disease • Hypertension • Immunology • Musculoskeletal Pain • Pediatrics

Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure. (ASH 2025) - "Treatment included prednisone in 284 (92.5%),mycophenolate in 145 (47.2%), azathioprine (AZA) in 144 (46.9%), a calcineurin inhibitor in 54 (17.6%),hydroxychloroquine in 51 (16.6%), extracorporeal photopheresis in 20 (6.5%), and rituximab in 10 (3.3%).A propensity score was calculated from the following unbalanced clinical factors: age (≥60 vs. <60), GvHDseverity (severe vs. mild/moderate), HCT-CI score (≥3 vs. <3), and treatment line (≥4th vs. <4th). The BEL group showed 72.0% [55.0–83.4] 12 months' FFS rate vs25.3% [10.6–43.1] for BAT (p<0.001), whereas 12 months' OS rates were 92.1% [77.3–97.4] and 88.4%[60.8–97.0] (p=0.317), respectively.Both univariate (UVA) and multivariate analysis (MVA) (BEL vs. BAT, HCT-CI ≥3, severe cGvHD, age ≥ 60,and previous acute GvHD) for FFS confirmed BEL superiority over BAT (hazard ratio (HR) 0.288 [0.155–0.535], p<0.001; no differences for the other factors). For OS, UVA showed that BEL had a trend for ahigher OS..."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program. (ASH 2025) - "Patients couldenter the MAP after at least two and a maximum of five prior lines of treatment (LOT) for chronic GvHD,which had to include ruxolitinib if not intolerant...Patients had a history of ruxolitiniband ibrutinib pre-treatment in 93% and 12%, respectively... This retrospective analysis of a large real-world cohort demonstrates efficacy and safety ofbelumosudil in refractory chronic GvHD patients. Dynamics of organ response are currently underinvestigation. Further prospective trials are needed to determine the duration of response and theimpact on GvHD-related mortality."

Retrospective data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Acute Respiratory Distress Syndrome • Chronic Graft versus Host Disease • CNS Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Herpes Zoster • Immunology • Infectious Disease • Leukemia • Lymphoma • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Nephrology • Non-melanoma Skin Cancer • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Septic Shock • Skin Cancer • Solid Tumor • Varicella Zoster

Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program (ASH 2025) - P, P2 | "The most common concomitant cGVHDmedications were belumosudil (65.4%), prednisone (60.6%), and ruxolitinib (51.0%). This EAP represents the largest collated experience of AXA treatment in cGVHD outside ofthe AGAVE-201 trial. The safety profile of AXA was consistent with that observed in clinical trials, and nonew or unexpected toxicities were reported. Patients received prior cGVHD treatments and had multi-organ involvement."

Clinical • Bone Marrow Transplantation • Cardiovascular • Chronic Graft versus Host Disease • Cough • Fibrosis • Gastrointestinal Disorder • Graft versus Host Disease • Heart Failure • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock • CSF1R

Response dynamics to belumosudil in chronic graft-versus-host disease: Characterizing late responses and organ-specific response expectations from the rockstar study (ASH 2025) - P2 | "Belumosudil achieved clinical responses across all involved organs in cGVHD. While mostparticipants experienced their first clinical response within approximately 3 months of therapy, a smallproportion had late responses, with 5.3% of all overall responses occurring after 6 months of treatment.Response kinetics varied by organ, with the most rapid responses seen in GI and joint/fascia involvement,and the highest rates of late responses observed in the lungs and eyes. These data underscore theimportance of tailoring clinical expectations and treatment duration based on organ-specific responsedynamics.Funding: This study was funded by Sanofi."

Chronic Graft versus Host Disease • Fibrosis • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Inflammation

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types (ASH 2025) - "Background : Chronic graft-versus-host disease (cGVHD) remains the leading cause of non-relapsemortality (NRM) in patients who undergo allogeneic stem cell transplantation (alloHCT), with a 50-70%incidence after calcineurin inhibitor (CNI) and methotrexate-based prophylaxis...Most patients receivedtacrolimus and mycophenolate mofetil (88%) or sirolimus (10%) in combination with PTCy...In patients who failed frontlinecorticosteroids, 71 (85%) patients received novel agents, with ruxolitinib being the most frequently usedfirst-line salvage agent in 70 (84%) patients, followed by infrequent use of other therapies—ECP,rituximab or belumosudil (n=8 each, 9.5%)... PTCy-based GVHD prophylaxis is associated with a lower incidence of moderate-to-severecGVHD, particularly fibrotic GVHD subtypes, when compared to conventional CNI-based prophylaxisregimens. Most patients who developed cGVHD responded to corticosteroids or ruxolitinib. Our datasupports the efficacy and versatility of..."

Post-transplantation • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Fibrosis • Graft versus Host Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis • Transplantation

Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival. (ASH 2025) - "The median interval from onset of cGvHD to BEL therapy was 46.1months (range 0.4-303).One hundred and twenty-seven pts (58.8%) received BEL as a monotherapy, while 89 (41.2%) received aBEL combination: 61 with ruxolitinib (BEL-RUX) (28.2%), 15 with RUX and extracorporeal photopheresis(ECP) (6.9%), and 13 with ECP only (6.0%). However, although the BEL-RUX group had a higher rate of prior RUXtherapy failure with a higher rate of overlap syndrome, no significant difference in FFS was observedbetween the two groups: the 12-month FFS rate was similar (71.2% for BEL vs. 66.2% for BEL-RUX), afteradjustment for overlap cGvHD and prior RUX exposure.ConclusionThe present study confirms therapeutic efficacy with impressive FFS at 6 and 12 months and an excellentsafety profile for heavily pretreated patients with SR-cGVHD. Combination therapy of BEL with RUXseems promising for patients with prior RUX therapy or those presenting with overlap syndrome."

Clinical • Clinical data • Real-world • Real-world evidence • Chronic Graft versus Host Disease • Dyspepsia • Graft versus Host Disease • Immunology • Infectious Disease • Respiratory Diseases • Retinal Disorders

Clinically meaningful improvement of the modified lee symptom score in patients treated with belumosudil for steroid-refractory chronic GVHD: Evidence from Canadian real-world outcomes (ASH 2025) - "While it is challenging to observe objective response in fibrotic component of cGvHDonly by NIH consensus criteria, the mLSS is a feasible and practical tool for capturing early clinicalimprovement, esp. fibrotic component, following BEL treatment, This highlights the importance oflongitudinal monitoring of the mLSS and the urgent need for a reliable tool to assess symptom burdenimprovement with novel cGVHD therapies."

Clinical • Real-world • Real-world evidence • Chronic Graft versus Host Disease • Fibrosis • Graft versus Host Disease • Immunology

Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety (ASH 2025) - "Belumosudil demonstrates robust anti-fibrotic activity in pediatric cGVHD, achieving highresponse rates in skin, joints, and pulmonary tissues. Early initiation within 3 months of cGVHD onset iscritical for optimal outcomes, particularly in visceral organs. The favorable safety profile supports itsconsideration as a preferred second-line therapy in this vulnerable population."

Retrospective data • Alopecia • Anemia • Aplastic Anemia • Beta-Thalassemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Fibrosis • Genetic Disorders • Graft versus Host Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the United States: A long-term follow-up analysis (ASH 2025) - "Prescription refills in pharmacy claim records wereused to determine RUX and prednisone-equivalent CS dosing and treatment length. Line of therapy forcGVHD medications was based on claims for CS, belumosudil, abatacept, alemtuzumab, RUX, etanercept,hydroxychloroquine, ibrutinib, imatinib, interleukin-2, methotrexate, mycophenolate mofetil, pentostatin,and rituximab after cGVHD diagnosis... Patients treated with RUX for cGVHD in real-world clinical practice remained on treatmentfor a median of 8 months; 40.9% remained on RUX for 1 year and 21.3% for 2 years, suggesting long-termpersistence of safety and ongoing clinical benefit. Median time from earliest CS fill for cGVHD todiscontinuation or reduction to low-dose CS was 77 days. By the end of 1-year follow-up, 90% of patientsachieved discontinuation or reduction to low-dose CS."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • IL2

Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study (ASH 2025) - P2 | "Among these 19 patients, demographics (median [range] age, 50.0 [20–73] y; male,63.2%) and baseline clinical characteristics (median [range] number of organs involved at baseline, 3.0 [2–8]; severe disease, 73.7%; prior use of ibrutinib, ruxolitinib, or belumosudil, 89.5%) were comparable tothe full cohort initially randomized to 0.3 mg/kg Q2W. Transition to 0.6 mg/kg Q4W (without dose capping) is feasible and well tolerated in patientstreated with axatilimab 0.3 mg/kg Q2W on the AGAVE-201 study. The Q4W dosing strategy at the 0.6mg/kg dose identified no new safety signals. Patients had a prolonged duration of therapy, with a medianof 20.9 months (1.7 y), and 84% of patients continued treatment, suggesting ongoing clinical benefit.These data provide evidence of the safety and feasibility of a 0.6 mg/kg Q4W dosing strategy in alignmentwith the AGAVE-201 protocol."

Clinical • Chronic Graft versus Host Disease • Fibrosis • Graft versus Host Disease • Immunology • Infectious Disease • Inflammation • Pneumonia • Respiratory Diseases • CSF1R

Changes in Immunosuppressive Treatment of Chronic Graft-Versus-Host Disease: Results from a Survey within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland (ASH 2024) - "Since the last survey, ruxolitinib (rux) has been approved and other agents are explored in treatment of cGVHD...For BOS, systemic and inhalative corticosteroids, montelukast and azithromycin (FAM), rux (14/19), ECP (16/19), CNI (9/19), and abatacept (9/19) are frequently applied agents, while belumosudil (7/19), imatinib (5/19) and ibrutinib (2/19) are used as salvage option in selected patients. In case of new sclerotic manifestations after failure of 2nd line treatment including steroids, CNI and rux, most centers would use ECP (13/19), whereas subsequent or alternative salvage treatment of sclerotic manifestations remains heterogenous comprising belumosudil (12/19), ibrutinib (5/19), imatinib (5/19), rituximab (4/19), cyclosporine (3/19), tacrolimus (3/19), everolimus (3/19), sirolimus (3/19), MTX (3/19) and MMF (3/19)...ECP is used in case of contraindication for rux and both agents are also used in progressive onset cGVHD. In contrast, treatment of BOS and..."

Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Transplantation